Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

February 7, 2019 by Alan Khadavi

Fezakinumab an IL-22 antagonist for Eczema

IL-22 upregulation characterizes atopic dermatitis lesions.  However, blocking IL-22 has not been defined in human subjects.  A recent study sought to evaluate the cellular and molecular effects of fezakinumab (anti-IL-22) versus placebo taken from biopsy specimens.

Atopic dermatitis is the most common chronic inflammatory skin disease with increasing prevalence.  IL-4 and IL-13 are the 2 lead cytokines that are upregulated in atopic dermatitis and they are inhibited through Dupilumab (Dupixent)

However, not every patient responds successfully and there are other pathways that may play a role in atopic dermatitis.  IL-22 has been postulated to be a main driver of epidermal hyperplasia and barrier defects.  IL-22 might be central to atopic dermatitis pathogenesis.  Fezakinumab has shown significant clinical improvements in patients with severe eczema disease.  Conclusions of the study showed:

  • Significant  improvement in the cutaneous gene signature with fezakinumab was only present in patients with high baseline IL-22 skin expression but not in those with low baseline IL-22 expression.
  • Downregulation of multiple immune pathways with fezakinumab was restricted to the IL-22 high group.

The study suggests the potential for personalized medicine in patients with atopic dermatitis.  The baseline expression of IL-22 may guide the therapy of an inhibitor such as fezakinumab.

Pharmaceutical medication is changing now and no longer the “one size fits all” approach is being used.  Diseases such as atopic dermatitis have different causes/triggers and a single medication may not be right for everyone.  We are seeing this currently in asthma where there are biologic medications for those who have IgE asthma (Xolair) or eosinophilic asthma (Nucala, Fasenra,Cinqair).

It is soon to tell if Fezakinumab will work for patients with eczema, but it seems to work in a particular subset of those patients.  As of now, the only biologic medication approved is Dupixent, otherwise mostly topical creams and conservative care are used to treat this condition.

Atopic Dermatitis (Eczema) Treatment

Treatment of Atopic Dermatitis (Eczema)

 

Filed Under: atopic dermatitis, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page